• Ender Dogan, Safak Yildirim Disli, Esra Asik, Seyhan Karacavus, and Feyyaz Ozdemir.
• Department of Medical Oncology, Kayseri City Education and Training Hospital, Kayseri, Turkey. enderdogandr1@gmail.com.
• Ir J Med Sci. 2024 Dec 18.

BackgroundA pathological complete response (pCR) rate after neoadjuvant chemotherapy (NAC) is important for the prognosis of early-stage breast cancer. The prediction of an NAC response plays a key role in managing neoadjuvant treatment.AimsThe aim of this study is to investigate the predictive value of the baseline PETCT FDG (F-18 fluoro-deoxy-glucose (FDG) positron emission tomography/computed tomography) SUVmax (the maximum standardized uptake value) for pCR after NAC in early-stage breast cancer.MethodsThe patients who performed PETCT before NAC were included in this retrospective study. The basal PETCT SUVmax values were divided into two categories based on the cutoff points of ≥ 8.77 or < 8.77, namely the low SUV max group and the high SUV max group. These two groups were compared according to the general characteristics. The impact of the PETCT SUVmax values on pCR was determined with logistic regression analyses.ResultsOne hundred forty-eight patients who performed PETCT before NAC were included in this retrospective study. Eighty-one patients were in the low SUV max group and 67 patients were in the high SUVmax group. The pCR trended toward a higher rate in the high SUVmax group than in low SUVmax group but it was not statistically significant (p = 0.052). The baseline PETCT SUVmax value was an independent predictive factor for pCR. (p = 0.025).ConclusionPETCT SUVmax may be a factor for the predicting complete response to neoadjuvant treatment in early-stage breast cancer.© 2024. The Author(s).

3 keywords...

hide…